SEC For	m 4 FORM	4 U	ΝΙΤ	ED STAT	ES SEC	URIT	IES	AN	D	EXCHA	ANG	ε	COM	MISSIC	DN			
·	Washington, D.C. 20549											OMB APPROVAL						
to Section 16. Form 4 or Form 5 obligations may continue. See					pursuant to S	T OF CHANGES IN BENEFICIAL OWNER pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									E	OMB Number: 3 Estimated average burde hours per response:		3235-0287 len 0.5
1. Name and Address of Reporting Person [*] Lock Kenneth A.					2. Issuer Name and Ticker or Trading Symbol <u>Arcutis Biotherapeutics, Inc.</u> [ARQT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below)				
	(Last)(First)(Middle)C/O ARCUTIS BIOTHERAPEUTICS, INC.3027 TOWNSGATE ROAD, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022								Chief Commercial Officer				
(Street) WESTLAKE CA 91361 VILLAGE				4. If Amendment, Date of Original Filed (Month/Day/Year)								 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 						
(City) (State) (Zip)																		
		Table	I - N	lon-Deriva	tive Secu	rities A	cqui	ired,	, Di	isposed (of, o	rВ	enefici	ally Ow	ned			
1. Title of Security (Instr. 3) Date (Month/Day/Yea				Execution		Transaction Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a						/ing I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	e V		Amount	(A) c (D)	or	Price	Tran	saction(s) r. 3 and 4)) [(iiisu. 4)	(1150.4)
Common Stock 03/01/202					2		S ⁽¹⁾			935	D		\$17.752	7 ⁽²⁾ 3	1,734 ⁽³⁾⁽⁴	4)	D	
		Ta	ble I	l - Derivati (e.g., pu	ive Securi Its, calls,										ed			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	Exe if an	Deemed cution Date, ly nth/Day/Year)	4. Transaction Code (Instr. 8)	E	Expiration Date A (Month/Day/Year) S				nou ecuri	e and nt of ities	8. Price o Derivative Security (Instr. 5)		tive ties	10. Ownership Form: Direct (D)	11. Nature of Indirec Beneficia Ownershi	

(1150.3)	Derivative Security	(Montili/Day/rear)	0)		Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Derivative Security (Instr. 3 and 4)		(1150.5)	Owned Following Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	(Instr. 4)	
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021.

2. The transaction was executed in multiple trades in prices ranging from \$17.40 to \$18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 1,002 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 964 shares on May 31, 2021 and 38 shares on November 30, 2021. 4. Includes 14,000 RSUs.

/s/ Scott Burrows, as

Attorney-in-Fact for Kenneth 03/03/2022 A. Lock

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.